Cuties

Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022

Retrieved on: 
Monday, November 7, 2022
Cuties, Merck, Food, Infection, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Private Securities Litigation Reform Act, Conference, Pyelonephritis, Tablet, COVID-19, Therapy, Marketing, U.S. Securities and Exchange Commission, NASDAQ, Bronchopneumonia, Fosfomycin, Urinary tract infection, Food and Drug Administration, Pharmaceutical industry

ET to discuss the financial results and recent corporate highlights.

Key Points: 
  • ET to discuss the financial results and recent corporate highlights.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics views as of the date of this press release.
  • These forward-looking statements should not be relied upon as representing Nabriva Therapeutics views as of any date subsequent to the date of this press release.

First Quality Introduces Size 8 Youth Diaper for More Inclusive Care

Retrieved on: 
Wednesday, July 20, 2022
Omni, First Quality, Incontinence, Walmart, Skin, GREAT, Parent, Marketing, Adult, Nursing, Paper, Caregiver, Efficiency, Boundless, LLC, Amazon, Child, Toy, Residential care, Financial adviser, Architecture, Cuties

GREAT NECK, N.Y., July 20, 2022 /PRNewswire/ -- First Quality has launched Boundless™ by Cuties®, a size 8 youth diaper for children with special needs who have outgrown baby diapers, but who are not yet ready for adult incontinence products. Boundless youth diapers aim to provide Complete Care for All, so that every child can feel confident and protected. 

Key Points: 
  • Boundless youth diapers aim to provide Complete Care for All, so that every child can feel confident and protected.
  • The first-of-its-kind youth diaper provides the same protection as a baby diaper but is designed to fit the frame of children who are 58 lbs.
  • "Boundless youth diapers were created to deliver inclusive care and better meet the needs of children, families and caregivers."
  • Learn more by visiting www.cuties.com
    First Quality is a registered trademark of First Quality Enterprises, Inc.
    Cutiesis a registered trademark of First Quality Baby Products, LLC.

Nabriva Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Highlights on May 5, 2022

Retrieved on: 
Monday, May 2, 2022
COVID-19, U.S. Securities and Exchange Commission, NASDAQ, GLOBE, Pyelonephritis, Private Securities Litigation Reform Act, Tablet, Food and Drug Administration, Cuties, Urinary tract infection, Food, Merck, ABSSSI, Patient, Infection, Review, Bronchopneumonia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Fosfomycin, Marketing, CF, Conference, Research, Therapy, Pharmaceutical industry

ET to discuss the financial results and recent corporate highlights.

Key Points: 
  • ET to discuss the financial results and recent corporate highlights.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics views as of the date of this press release.
  • These forward-looking statements should not be relied upon as representing Nabriva Therapeutics views as of any date subsequent to the date of this press release.

Nabriva Therapeutics to Report 2021 Financial Results and Recent Corporate Highlights on March 29, 2022

Retrieved on: 
Tuesday, March 15, 2022
Therapy, U.S. Securities and Exchange Commission, GLOBE, Review, Food and Drug Administration, Private Securities Litigation Reform Act, Conference, COVID-19, Cuties, Infection, Bronchopneumonia, Pyelonephritis, Tablet, NASDAQ, ABSSSI, Urinary tract infection, Fosfomycin, Food, Union, Research, Complicated, Merck, CF, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Marketing, Pharmaceutical industry

ET to discuss the financial results and recent corporate highlights.

Key Points: 
  • ET to discuss the financial results and recent corporate highlights.
  • A live webcast of the conference call can be accessed through the Investors tab on the Nabriva Therapeutics website at www.nabriva.com.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • These forward-looking statements should not be relied upon as representing Nabriva Therapeutics views as of any date subsequent to the date of this press release.

Nabriva Therapeutics to Adjourn Extraordinary General Meeting of Shareholders on December 22, 2021

Retrieved on: 
Wednesday, December 22, 2021
U.S. Securities and Exchange Commission, Merck, Urinary tract infection, Pyelonephritis, Internet, Telephone, Infection, NASDAQ, Bronchopneumonia, Proxy statement, Private Securities Litigation Reform Act, Method, Proxy, SEC, Food and Drug Administration, Cuties, Tablet, EGM, Company, Fosfomycin, Therapy, Security (finance), Food, GLOBE, Animal

Nabriva Therapeutics is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.

Key Points: 
  • Nabriva Therapeutics is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.
  • In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics views as of the date of this press release.
  • However, while Nabriva Therapeutics may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.
  • These forward-looking statements should not be relied upon as representing Nabriva Therapeutics views as of any date subsequent to the date of this press release.

Lefamulin NDA Filed in Mainland China for Treatment of Community Acquired Pneumonia

Retrieved on: 
Monday, November 29, 2021
Patient, CAP, Review, Bronchopneumonia, Merck, Private Securities Litigation Reform Act, Awareness, Sumitomo Group, CDE, SEC, Sumitomo Dainippon Pharma, COVID-19, Food and Drug Administration, Community-acquired pneumonia, GLOBE, Infection, Tablet, NDA, Cuties, Lefamulin, Fosfomycin, Therapy, Pyelonephritis, Growth, NASDAQ, Urinary tract infection, Food, Hercules, Pharmaceutical industry

This filing brings Nabriva and Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. one step closer to their goal of offering lefamulin to patients with CAP in China.

Key Points: 
  • This filing brings Nabriva and Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. one step closer to their goal of offering lefamulin to patients with CAP in China.
  • To date there have been 4 approvals and two applications pending review, said Ted Schroeder, Chief Executive Officer of Nabriva Therapeutics.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).

Nabriva Therapeutics to Report Third Quarter 2021 Financial Results and Recent Corporate Highlights on November 9, 2021

Retrieved on: 
Tuesday, October 26, 2021
Infection, Bronchopneumonia, Tablet, Merck, Cuties, Patient, Private Securities Litigation Reform Act, NASDAQ, Food, SEC, Fosfomycin, Conference, Urinary tract infection, COVID-19, Awareness, Growth, Hercules, Pyelonephritis, Therapy, Food and Drug Administration, GLOBE, Pharmaceutical industry

ET to discuss the financial results and recent corporate highlights.

Key Points: 
  • ET to discuss the financial results and recent corporate highlights.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics views as of the date of this press release.
  • These forward-looking statements should not be relied upon as representing Nabriva Therapeutics views as of any date subsequent to the date of this press release.

Nabriva Therapeutics Appoints Dr. Christine Guico-Pabia, M.D., as Chief Medical Officer

Retrieved on: 
Friday, October 1, 2021
McKesson Corporation, Food, Infection, Therapy, Tablet, Urinary tract infection, NASDAQ, Private Securities Litigation Reform Act, Metagenics, Johns Hopkins Bloomberg School of Public Health, Patient, Wyeth, Bronchopneumonia, Business, Merck, Food and Drug Administration, CMO, Pyelonephritis, University, MPH, Johns Hopkins University, COVID-19, Public health, MBA, Drug development, Fosfomycin, Cuties, SEC, GLOBE, Pharmaceutical industry

Christine Guico-Pabia, M.D., MBA, MPH as Chief Medical Officer (CMO) effective October 1, 2021.

Key Points: 
  • Christine Guico-Pabia, M.D., MBA, MPH as Chief Medical Officer (CMO) effective October 1, 2021.
  • Christine brings a well-rounded profile to the CMO role, with extensive experience across several therapeutic areas from clinical development through to the post-marketing support of multiple commercial stage products over the course of her notable career, said Ted Schroeder, Chief Executive Officer of Nabriva Therapeutics.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • These forward-looking statements should not be relied upon as representing Nabriva Therapeutics views as of any date subsequent to the date of this press release.

Nabriva Therapeutics to Present Data at IDWeek 2021

Retrieved on: 
Friday, September 24, 2021
Tablet, Food, Therapy, Infection, Infectious Diseases Society of America, Urinary tract infection, NASDAQ, Private Securities Litigation Reform Act, Patient, Hercules, Bronchopneumonia, Food and Drug Administration, Pyelonephritis, Merck, Growth, Awareness, Staphylococcus aureus, COVID-19, IDSA, Fosfomycin, Cuties, Cystic fibrosis, SEC, GLOBE, Pharmaceutical industry

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.

Key Points: 
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.
  • In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics views as of the date of this press release.
  • These forward-looking statements should not be relied upon as representing Nabriva Therapeutics views as of any date subsequent to the date of this press release.

Nabriva and Vizient Enter into Agreement to Make XENLETA® (lefamulin) Available to Vizient’s Pharmacy Network Program

Retrieved on: 
Thursday, September 9, 2021

Nabriva CEO Ted Schroeder commented, We are excited by Vizients decision to enter into an agreement to make XENLETA available to their Hospital Pharmacy Network, enabling access across Vizient member hospitals, which make up more than half of U.S. hospitals.

Key Points: 
  • Nabriva CEO Ted Schroeder commented, We are excited by Vizients decision to enter into an agreement to make XENLETA available to their Hospital Pharmacy Network, enabling access across Vizient member hospitals, which make up more than half of U.S. hospitals.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
  • These forward-looking statements should not be relied upon as representing Nabriva Therapeutics views as of any date subsequent to the date of this press release.